CLAIMS

1. A salt selected from the group consisting of:

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt;

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt; and

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt;

wherein the salt is crystalline.

2. The crystalline salt of claim 1 which is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.

3. The crystalline salt of claim 1 which is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt.

4. The crystalline salt of claim 1 which is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt.

5. The crystalline salt of claim 2 wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.

6. The crystalline salt of claim 3, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:sulfuric acid salt.

7. The crystalline salt of claim 4 wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:maleic acid salt.

8. A pharmaceutical formulation comprising the crystalline salt of any one of claims 1 to 7 and a pharmaceutically acceptable carrier.

9. A dosage form comprising a crystalline salt selected from the group consisting of

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt,

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile sulfuric acid salt, and

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1 H-pyrazol-1-yl)-3-cyclopentylpropanenitrile maleic acid salt.

10. A dosage form comprising the pharmaceutical formulation of claim 8.

11. The dosage form of claim 9 or claim 10, wherein the dosage form is suitable for oral administration.

12. The dosage form of claim 11, wherein the dosage form is a tablet.